deucravacitinib
bms
[' psa', '#2133', 'deucra']
fitzgerald et al. psa patients with higher levels of il-23-il-17 pathway biomarkers more likely to benefit from tyk2i deucravacitinib #acr22 abstr#2133 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC